Cíl: Montrealský kognitivní test (MoCA) je jednou z nejpoužívanějších screeningových zkoušek kognice u dospělých osob, pro něž existují normy pro českou populaci. Varianta MoCA-22, která je určena pro osoby s poruchami zraku či imobilitou horních končetin, se dá administrovat i po telefonu. Tato studie přináší české normy MoCA-22. Materiál a metodika: Soubor (n = 1 049) se skládá z účastníků čtyř studií provedených v ČR. Zařazeny byly osoby ve věku 19–98 let, bez neurodegenerativního, psychiatrického či jiného závažného onemocnění. Data pro MoCA-22 byla odvozena z dat získaných vyšetřením standardní verzí MoCA. V souladu se zavedenou klinickou praxí i statistickou analýzou jsou soubor a odvozené normy rozděleny na tři věkové kategorie: 19–50 let, 51–74 let, 75 a více let. Výsledky: Pro výše uvedené věkové kategorie dále rozdělené dle dosaženého vzdělání (nižší, vyšší) předkládáme průměrné skóry i odhadované percentilové hranice. Výkon v MoCA-22 je ovlivněn dosaženým vzděláním a věkem, ale nikoli pohlavím. Pro úpravu výsledků dle demografických faktorů proto poskytujeme i regresní rovnici. Závěr: Normativní údaje pro MoCA-22 rozšíří klinické instrumentárium v Česku a umožní adekvátní screening kognice u osob, jež jsou zdravotním stavem limitovány při využití standardních metod.

Aim: The Montreal Cognitive Assessment (MoCA) is one of the most widely used cognitive screening tests in adults with reference standards for the Czech population. The MoCA-22 variant is designed for individuals with visual impairment or upper limb immobility and can be administered over the telephone. This study presents the Czech MoCA-22 normative standards. Materials and methods: The sample (N = 1,049) consists of participants from four studies conducted in the Czech Republic. The subjects included were aged 19–98 years, and were without neurodegenerative, psychiatric, or other serious illness. Data for the MoCA-22 were derived from data obtained by the standard version of MoCA. Following established clinical practice and statistical analysis, the population and derived norms are divided into three age categories: 19–50 years, 51–74 years, and 75 years and older. Results: For these age categories above, which were further subdivided by educational status (lower, higher), we present mean scores and estimated percentile thresholds. Performance in the MoCA-22 is affected by demoraphic factors, such as educational status and age but not sex, as reflected by the regression equation. Conclusions: Normative data for MoCA-22 will complement the clinical armamentarium in Czechia and allow adequate cognitive screening in people whose health status limits them when using standard methods.

• Keywords
• Montrealský kognitivní test (MoCA),
• MeSH
• Clinical Studies as Topic MeSH
• Cognition Disorders diagnosis   MeSH
• Humans MeSH
• Neuropsychological Tests * standards   MeSH
• Bedridden Persons MeSH
• Telephone MeSH
• Telemedicine MeSH
• Persons with Visual Disabilities MeSH
• Check Tag
• Humans MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

BACKGROUND: The rapid increase in cannabis use during pregnancy-up by 170 % between 2009 and 2016-raises pressing concerns about its effects on fetal health, particularly on the delicate monoamine system within the fetoplacental unit, which is crucial for placental function and neurodevelopment. OBJECTIVE: This systematic review explores the impact of prenatal cannabinoid exposure on the monoamine system within the fetoplacental unit, with a focus on its implications for fetal development through the lens of the Developmental Origins of Health and Disease (DOHaD) framework. METHODS: A comprehensive search across multiple databases initially retrieved 18,252 papers. After rigorous screening, only 16 animal studies and 4 human studies met the inclusion criteria. Findings were synthesized to evaluate the effects of prenatal cannabis exposure on neurotransmitter regulation, receptor function, and gene expression. RESULTS: Although no studies directly addressed the monoamine system in the placenta, animal models revealed significant disruptions in neurotransmitter regulation and neurodevelopmental changes following prenatal cannabis exposure. Human studies suggested potential cognitive and behavioral risks for offspring exposed in utero. CONCLUSION: This review exposes a critical gap in the literature on cannabis' effects on the placental monoamine system. While evidence points to notable neurodevelopmental risks, the scarcity of focused research underscores the need for further investigation to fully understand the implications of prenatal cannabis exposure.

• MeSH
• Biogenic Monoamines metabolism   MeSH
• Cannabinoids * metabolism   MeSH
• Humans MeSH
• Placenta * metabolism   drug effects   MeSH
• Pregnancy MeSH
• Fetal Development drug effects   MeSH
• Prenatal Exposure Delayed Effects * metabolism   MeSH
• Animals MeSH
• Check Tag
• Humans MeSH
• Pregnancy MeSH
• Female MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Review MeSH
• Systematic Review MeSH

Kognitívna porucha (KP) po ischemickej cievnej mozgovej príhode (CMP) je častým fenoménom. U niektorých pacientov môže KP pretrvávať aj dlhý čas po prekonanej CMP, čo sa v anglickej literatúre označuje ako PCSI - post stroke cognitive impairment. Ide o osobitnú nozologickú jednotku, ktorú je potrebné začať diagnostikovať už počas hospitalizácie, no definitívnu diagnózu je možné vykonať až následne kontrolným vyšetrením kognitívnych funkcií s odstupom šesť mesiacov od CMP. Článok prináša aktuálny prehľad o diagnostike, predikcii a terapii PSCI ako osobitnej nozologickej jednotky.

Cognitive impairment (CI) after stroke is a frequent phenomenon. In some patients, CI can persist for a long time after overcoming stroke, which is referred to in the English literature as PCSI - post stroke cognitive impairment. It is a special nosological entity that needs to be diagnosed already during hospitalization, but a definitive diagnosis can only be made subsequently by a control examination of cognitive functions six months after stroke. The following article provides an up-to-date overview of the diagnosis, prediction and therapy of PSCI as a special nosological unit.

• MeSH
• Stroke * diagnosis   complications   physiopathology   MeSH
• Dementia diagnosis   etiology   MeSH
• Diagnosis, Differential MeSH
• Cognitive Dysfunction * diagnosis   etiology   drug therapy   physiopathology   MeSH
• Humans MeSH
• Disease Management MeSH
• Neuroimaging classification   methods   MeSH
• Mental Status and Dementia Tests MeSH
• Check Tag
• Humans MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH
• Review MeSH

BACKGROUND: Individuals with adverse pregnancy outcomes have an increased risk of cerebrovascular disease, but the association between adverse pregnancy outcomes and cognitive impairment and dementia is less well established. We aimed to synthesise, combine, and assess the growing body of data examining the associations between adverse pregnancy outcomes and mild cognitive impairment and dementia in parous women. METHODS: In this systematic review and meta-analysis, we searched PubMed (MEDLINE), Web of Science, and Embase from database inception up to July 18, 2024, with no language restrictions, for observational studies or clinical trials that reported mild cognitive impairment or dementia as outcomes and included female individuals or women who had an adverse pregnancy outcome, including hypertensive disorders of pregnancy, gestational diabetes, stillbirth, fetal growth restriction, preterm birth, or placental abruption. We excluded studies of men, nulliparous women, women with pre-pregnancy conditions associated with impaired cognition, and studies examining cognitive impairment within 6 months of pregnancy. Database searches were supplemented by manual review of the reference lists of included studies. If studies met eligibility criteria but did not have sufficient data for meta-analysis (ie, did not report a summary statistic or a hazard ratio [HR] for outcome estimation), they were included in the systematic review and excluded from the meta-analysis. After removing duplicates, two investigators independently screened titles and abstracts using Covidence software, with potentially eligible studies undergoing full-text review by the same reviewers, with further review by a third reviewer and disagreements resolved by discussion and group consensus. Study quality was assessed and summary statistics extracted by two reviewers independently. The primary outcomes of our study were mild cognitive impairment, all-cause dementia, Alzheimer's disease, and vascular dementia. Heterogeneity was measured using the Q test and I2 statistic, and we used random-effects models with inverse-variance weighting to assess the association between adverse pregnancy outcome and primary outcomes with sufficient meta-analysable data via pooled adjusted HRs and 95% CIs. The study protocol was registered with PROSPERO, CRD42023453511. FINDINGS: Of 11 251 publications identified, 15 studies (including 7 347 202 participants) met inclusion criteria for the systematic review, and 11 studies (6 263 431 participants) had sufficient data for meta-analysis. A history of any adverse pregnancy outcome was associated with higher risk of all-cause dementia (adjusted HR 1·32 [95% CI 1·17-1·49]; I2= 80%), Alzheimer's disease (1·26 [1·04-1·53]; I2=63%), and vascular dementia (1·94 [1·70-2·21]; I2=0%). A history of any hypertensive disorder of pregnancy was significantly associated with all-cause dementia (1·32 [1·11-1·57]; I2=74%) and vascular dementia (1·78 [1·46-2·17]; I2=0%), but not Alzheimer's disease (1·24 [0·98-1·57]; I2=66%). Stillbirth was not significantly associated with higher risk of all-cause dementia (1·26 [95% CI 0·93-1·71]; I2=62%). In individual studies, similar effect directions were observed for preterm birth and fetal growth restriction, but data were insufficient for meta-analysis. INTERPRETATION: Given their increased risk of dementia, women with a history of adverse pregnancy outcomes should be evaluated for additional dementia risk factors and monitored closely for any signs of cognitive decline. Furthermore, to obtain more reliable findings, future studies should measure both exposures and outcomes prospectively and objectively. FUNDING: National Institutes of Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, and National Heart, Lung and Blood Institute.

• MeSH
• Dementia * epidemiology   psychology   MeSH
• Cognitive Dysfunction * epidemiology   psychology   MeSH
• Humans MeSH
• Pregnancy MeSH
• Pregnancy Outcome * epidemiology   psychology   MeSH
• Check Tag
• Humans MeSH
• Pregnancy MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Meta-Analysis MeSH
• Systematic Review MeSH

Cíl: Cílem výzkumu bylo posouzení kognitivních funkcí u seniorů v domovech pro seniory prostřednictvím standardizovaných testů – Montrealský kognitivní test (MoCA) a Pojmenování obrázků a jejich vybavení (POBAV). Metodika: Výzkum zahrnoval 76 klientů ze tří domovů pro seniory. Hodnocení kognitivních funkcí bylo provedeno standardizovanými testy MoCA a POBAV (ježková verze). Statistické zpracování bylo provedeno na hladině významnosti a = 0,05. Výsledky: Průměrný skór v MoCA byl 20 bodů, průměrné výsledky u POBAV byly 3/5. Normální kognitivní stav mělo dle MoCA (při hraničním skóre ≤ 24 bodů) 21 % seniorů a dle POBAV dosáhlo normy 25 % dotázaných. U obou testů MoCA a POBAV nebyl zjištěn statisticky významný rozdíl v úrovni kognitivních funkcí v závislosti na pohlaví, vzdělání ani na délce pobytu v domově pro seniory. Byl však prokázán statisticky významný rozdíl v úrovni kognitivních funkcí v závislosti na věku, kognitivním tréninku i na kondičním cvičení a bylo zjištěno, že osoby absolvující kognitivní trénink a kondiční cvičení dosahují v obou testech lepších výsledků. Byla potvrzena shoda v detekci kognitivní poruchy pomocí MoCA a POBAV v 97 % případů. Mezi testy MoCA a POBAV byla zjištěna významná korelace. Pearsonův korelační koeficient mezi testy MoCA a POBAV – Chyby v pojmenování obrázků, znázorňuje negativní korelaci –0,625 (p < 0,001). Pearsonův korelační koeficient mezi testy MoCA a POBAV – Správně vybavené obrázky, představuje pozitivní korelaci 0,86 (p < 0,001). Závěr: Časný záchyt a monitoring kognitivního deficitu pomocí screeningových testů by měly být nedílnou součástí při poskytování dlouhodobé péče u seniorů. Test POBAV je vhodnou volbou pro včasný záchyt kognitivního deficitu a může sloužit jako srovnatelná alternativa testu MoCA.

Aim: The aim of the research was to assess cognitive functions of elderly people in nursing homes using standardized tests – Montreal Cognitive Assessment (MoCA) and Picture Naming and Immediate Recall (PICNIR). Methodology: The study included 76 clients from three nursing homes. The assessment of cognitive functions was carried out using the standardized tests MoCA and PICNIR (Hedgehog Version). Statistical processing was performed at a significance level of α = 0.05. Results: The average score in MoCA was 20 points, and the average results in PICNIR were 3/5. According to MoCA (with a threshold score of ≤ 24 points), 21% of elderly people had a normal cognitive state, and according to PICNIR, 25% of respondents reached the norm. No statistically significant difference in the level of cognitive functions was found in either the MoCA or PICNIR tests in relation to sex, education, or length of stay in the nursing home. However, a statistically significant difference in the level of cognitive functions was demonstrated in relation to age, cognitive training, and physical exercise, and it was found that individuals undergoing cognitive training and physical exercise achieved better results in both tests. A concordance in the detection of cognitive impairment using MoCA and PICNIR was confirmed in 97% of cases. A significant correlation was found between the MoCA and PICNIR tests. The Pearson correlation coefficient between MoCA and PICNIR – Mistakes in Naming demonstrated a negative correlation of –0.625 (P < 0.001). The Pearson correlation coefficient between MoCA and PICNIR – Correctly Recalled Picture Names indicated a positive correlation of 0.86 (P < 0.001). Conclusion: Early detection and monitoring of cognitive deficits using screening tests should be an integral part of providing long-term care for elderly people. The PICNIR test is a suitable choice for early detection of cognitive deficits and can serve as a comparable alternative to the MoCA test.

• MeSH
• Homes for the Aged statistics & numerical data   MeSH
• Epidemiologic Studies MeSH
• Cognition MeSH
• Correlation of Data MeSH
• Humans MeSH
• Neurocognitive Disorders * diagnosis   epidemiology   MeSH
• Neuropsychological Tests * statistics & numerical data   MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Mental Status and Dementia Tests statistics & numerical data   MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH

Neuropsychiatric symptoms (NPS) are common in hereditary ataxias as a part of the cerebellar cognitive affective syndrome. In Friedreich ataxia (FRDA), one of the most common hereditary ataxias, depressive symptoms were previously reported, but little is known about other NPS. We aimed to study the presence and severity of a broad range of NPS in individuals with FRDA and assess the relationship between the NPS and the disease severity, cognition, and quality of life and to examine the concordance between the NPS reported by the patients and by their informants. Mild Behavioral Impairment Checklist (MBI-C), a questionnaire designed for screening NPS in the early stages of neurodegenerative diseases, was administered to informants of individuals with FRDA and healthy controls and to people with FRDA themselves. Compared to healthy controls, patients with FRDA scored significantly higher in the total MBI-C score, emotion dysregulation domain (corresponding to depression and anxiety), and decreased motivation domain. When assessed by caregiver, the total MBI-C score and several NPS domains correlated with activities of daily living. Only psychotic symptoms were related to ataxia severity and general cognition. When endorsed by patients, only the relation between few MBI-C domains and quality of life was observed. We found slight to moderate agreement between informant-rated and patient-rated scores. NPS, particularly emotion dysregulation and decreased motivation, are common and clinically relevant in FRDA and should receive more attention due to their potential impact on quality of life and the possibility of therapeutic intervention.

• MeSH
• Activities of Daily Living MeSH
• Depression etiology   MeSH
• Adult MeSH
• Friedreich Ataxia * psychology   complications   MeSH
• Cognition MeSH
• Quality of Life * MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Surveys and Questionnaires MeSH
• Case-Control Studies MeSH
• Severity of Illness Index MeSH
• Anxiety MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

BACKGROUND: The spread of tau pathology closely correlates with the disease course and cognitive decline in Alzheimer's disease (AD). Tau-targeting immunotherapies are being developed to stop the spread of tau pathology and thus halt disease progression. In this post hoc analysis of the ADAMANT clinical trial, we examined the performance of AADvac1, an active immunotherapy targeting the microtubule-binding region (MTBR) of tau, in a subgroup of participants with elevated plasma p-tau217, indicating AD-related neuropathological changes. METHODS: ADAMANT was a 24-month, randomized, placebo-controlled, parallel-group, double-blinded, multicenter, phase 2 clinical trial in subjects with mild AD. The trial participants were randomized 3:2 to receive six doses of AADvac1 or placebo at 4-week intervals, followed by five booster doses at 14-week intervals. The primary outcome was safety. The secondary outcomes were the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Cooperative Study - Activities of Daily Living score for Mild Cognitive Impairment 18-item version (ADCS-ADL-MCI-18), and immunogenicity. Volumetric MRI, plasma neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) were exploratory outcomes. The inclusion criterion for this post-hoc analysis was a baseline plasma p-tau217 level above the cutoff for AD. RESULTS: Among 196 ADAMANT participants, 137 were positive for plasma p-tau217 (mean age 71.4 years, 59% women). AADvac1 was safe and well tolerated in this subgroup. AADvac1 reduced the rate of accumulation of log-plasma NfL by 56% and that of GFAP by 73%. The treatment differences in the CDR-SB and ADCS-ADL-MCI-18 scores favored AADvac1 but were not statistically significant. AADvac1 had no effect on whole-brain volume but nonsignificantly reduced the loss of brain cortical tissue in several regions. Importantly, the impact on the study outcomes was more pronounced in participants with higher anti-tau antibody levels. CONCLUSIONS: These results suggest that AADvac1 tau immunotherapy can reduce plasma biomarkers of neurodegeneration and neuroinflammation. These findings and possible observations on brain atrophy and cognition are hypothesis-generating and warrant further evaluation in a larger clinical trial. TRIAL REGISTRATION: EudraCT 2015-000630-30 (primary) and NCT02579252.

• MeSH
• Immunotherapy, Active methods   MeSH
• Alzheimer Disease * blood   therapy   immunology   MeSH
• Biomarkers blood   MeSH
• Double-Blind Method MeSH
• Middle Aged MeSH
• Humans MeSH
• tau Proteins * blood   MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Mental Status and Dementia Tests MeSH
• Treatment Outcome MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Clinical Trial, Phase II MeSH
• Multicenter Study MeSH
• Randomized Controlled Trial MeSH

BACKGROUND: Over 55 million people worldwide are living with dementia. The rate of cognitive decline increases with age, and loss of senses may be a contributing factor. OBJECTIVES: This study aimed to analyze hearing, olfactory function, and color vision in patients with dementia. MATERIALS AND METHODS: The sample comprised 40 patients with dementia and 37 cognitively normal controls aged 41-85 years. All participants underwent conventional pure-tone audiometry and a screening version of the Hearing Handicap Inventory for Adults, the Odorized Markers Test of olfactory function and the Ishihara color vision test. The effects of comorbidities and lifestyle factors were also assessed. RESULTS: Patients with dementia had significantly worse hearing at almost all frequencies tested and significantly greater olfactory impairment than cognitively normal controls. Color vision impairment was found in less than 8% of the sample, with no significant difference between the groups. Impairment of two senses (hearing and olfaction) was significantly more common in patients with dementia than in controls. CONCLUSION: Individuals with dementia were found to have sensory decline, namely hearing and olfactory impairment. Color vision was rarely impaired in the sample. Participants with dementia tended to have more multisensory impairments than controls.

• Publication type
• Journal Article MeSH

Nedoslýchavost a hluchota patří mezi nejzávažnější smyslové vady. Obvykle se jedná o vrozené poruchy a v případě genetického podkladu se nejčastěji dědí autozomálně recesivně. Jejich časný záchyt je stěžejní, neboť normální sluch je zásadní pro vývoj řeči, kognice a komunikace. Metodou sekundární prevence je screening, který se v České republice provádí dle metodických pokynů u novorozenců a pětiletých dětí. Předkládané sdělení se věnuje jednotlivým užívaným metodám screeningového vyšetření sluchu u dětí. Korespondující autor: MUDr. Pavel Hermann Alfamedica, s.r.o. Mánesova 1056/41 120 00 Praha 2 info@usni.cz

Hearing loss and deafness are among the most serious sensory defects. These are usually congenital disorders and in the case of genetic background are most often inherited autosomal recessively. Their early detection is crucial as normal hearing is essential for the development of speech, cognition and communication. The secondary prevention method is screening, which according to the methodological guidelines is carried out in the Czech Republic in newborns and five-year-old children. The presented articles deals with the individual methods used.

• MeSH
• Deafness prevention & control   MeSH
• Humans MeSH
• Hearing Loss * prevention & control   MeSH
• Infant, Newborn MeSH
• Neonatal Screening methods   organization & administration   MeSH
• Hearing Disorders classification   prevention & control   MeSH
• Child, Preschool MeSH
• Secondary Prevention * methods   organization & administration   statistics & numerical data   MeSH
• Check Tag
• Humans MeSH
• Infant, Newborn MeSH
• Child, Preschool MeSH
• Publication type
• Review MeSH

BACKGROUND: Semantic and short-term episodic memory are impaired in some brain disorders including Alzheimer's disease. OBJECTIVE: Development and validation of an almost self-administered, but cognitively demanding four-minute test identifying very mild cognitive impairment (vMCI). METHODS: The innovative hedgehog PICture Naming and Immediate Recall (PICNIR) consisted of two parts. The first task was to write down the names of 20 black-and-white pictures to evaluate long-term semantic memory and language. The second task involves immediate recall and writing the names of as many previously named pictures as possible in one minute. The PICNIR is assessed using the number of naming errors (NE) and correctly recalled picture names (PICR). The PICNIR and a neuropsychological battery were administered to 190 elderly individuals living independently in the community. They were divided into those with vMCI (n = 43 with Montreal Cognitive Assessment (MoCA) 24 ± 3 points) and sociodemographically matched cognitively normal (CN) individuals (n = 147 with MoCA 26 ± 3). Both subgroups had predicted mean Mini-Mental State Examination scores of 28-29 points. RESULTS: Compared to CN, vMCI participants made more NE (0.3 ± 0.6 versus 0.6 ± 0.9; p = 0.02) and recalled fewer PICR (8.9 ± 2.2 versus 6.8 ± 2.2; p < 0.000001). Discriminative validity was satisfactory using the area under the ROC curve (AUC): 0.76 for PICR, 0.74 for MoCA, 0.67 for MoCA-five-word recall, and 0.59 for NE. The AUCs of PICR and MoCA were comparable and larger than those of MoCA five-point recall or NE. Logical Memory scores, RAVLT scores, Digit symbol, and animal fluency correlated with PICR. CONCLUSIONS: The picture-based PICNIR is an ultra-brief, sensitive cognitive test valid for assessing very mild cognitive impairment. Its effectiveness should be validated for other languages and cultures.

• MeSH
• Memory, Episodic * MeSH
• Cognitive Dysfunction * diagnosis   psychology   MeSH
• Memory, Short-Term physiology   MeSH
• Humans MeSH
• Neuropsychological Tests * statistics & numerical data   MeSH
• Reproducibility of Results MeSH
• Mental Recall * physiology   MeSH
• Semantics MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Mental Status and Dementia Tests statistics & numerical data   MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH